Supercharged immune cells battle tough melanomas in new trial
NCT ID NCT06961357
Summary
This early-stage trial is testing a personalized cell therapy for people with advanced melanoma that hasn't responded to standard treatments. Doctors take immune cells from a patient's own tumor, boost them in the lab with a protein called CD40L, and then infuse them back into the patient after a brief chemotherapy regimen. The main goals are to see if this approach is safe and if it can shrink tumors in patients with different types of advanced melanoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Conditions
Explore the condition pages connected to this study.